Taxanes in the Treatment of Advanced Gastric Cancer
Byung Woog Kang,
Oh-Kyoung Kwon,
Ho Young Chung,
Wansik Yu,
Jong Gwang Kim
Affiliations
Byung Woog Kang
Department of Oncology/Hematology, Kyungpook National University Medical Center, Kyungpook National University School of Medicine, Kyungpook National University Cancer Research Institute, 807 Hogukno, buk-gu, Daegu 41404, Korea
Oh-Kyoung Kwon
Department of Surgery, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu 41494, Korea
Ho Young Chung
Department of Surgery, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu 41494, Korea
Wansik Yu
Department of Surgery, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu 41494, Korea
Jong Gwang Kim
Department of Oncology/Hematology, Kyungpook National University Medical Center, Kyungpook National University School of Medicine, Kyungpook National University Cancer Research Institute, 807 Hogukno, buk-gu, Daegu 41404, Korea
Although rapid advances in treatment options have improved the prognosis of advanced gastric cancer (AGC), it remains a major public health problem and the second leading cause of cancer-related deaths in the world. Taxanes (paclitaxel and docetaxel) are microtubule stabilizing agents that inhibit the process of cell division, and have shown antitumor activity in the treatment of AGC as a single or combination chemotherapy. Accordingly, this review focuses on the efficacy and tolerability of taxanes in the first- or second-line chemotherapy setting for AGC.
